| 2.47 0.17 (7.39%) | 11-29 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.85 | 1-year : | 4.74 |
| Resists | First : | 3.3 | Second : | 4.05 |
| Pivot price | 3.05  |
|||
| Supports | First : | 2.07 | Second : | 1.73 |
| MAs | MA(5) : | 2.63 |
MA(20) : | 3.23 |
| MA(100) : | 3.56 |
MA(250) : | 3.43 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.6  |
D(3) : | 12.4 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 6.05 | Low : | 2.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VIGL ] has closed above bottom band by 16.2%. Bollinger Bands are 85.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.34 - 2.36 | 2.36 - 2.37 |
| Low: | 2.1 - 2.11 | 2.11 - 2.13 |
| Close: | 2.28 - 2.3 | 2.3 - 2.32 |
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Sat, 30 Nov 2024
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
Tue, 26 Nov 2024
Vigil Neuroscience's (VIGL) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
Thu, 14 Nov 2024
Deep Track Capital, LP Increases Stake in Vigil Neuroscience Inc - GuruFocus.com
Thu, 07 Nov 2024
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - StockTitan
Thu, 07 Nov 2024
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Thu, 07 Nov 2024
Vigil Neuroscience Inc (VIGL) Quarterly 10-Q Report - Quartzy
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 21.2 (%) |
| Held by Institutions | 80.1 (%) |
| Shares Short | 513 (K) |
| Shares Short P.Month | 547 (K) |
| EPS | -2.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.7 % |
| Return on Equity (ttm) | -70.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -70 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -1.2 |
| PEG Ratio | 0 |
| Price to Book value | 0.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|